CTOs on the Move

Ecovative Design

www.ecovativedesign.com

 
Ecovative uses biology to solve fundamental human needs at industrial scales and in consumer applications. Ecovative uses mycelium to grow category defining products ranging from leather like textiles to sustainable packaging to high performance foams for apparel and beauty.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ecovative Design raised $10M on 10/11/2019

Similar Companies

Navigate BioPharma

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.

Organix Inc.

Organix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

SkinMedica

SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets

Aradigm Corporation

Aradigm Corporation is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.